CA-NETAPP
10.5.2022 14:02:04 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced that NetApp EF600 all-flash NVMe storage combined with the BeeGFS parallel file system is now certified for NVIDIA DGX SuperPOD ™. The new certification simplifies artificial intelligence (AI) and high-performance computing (HPC) infrastructure to enable faster implementation of these use cases.
Since 2018, NetApp and NVIDIA have served hundreds of customers with a range of solutions, from building AI Centers of Excellence to solving massive-scale AI training challenges. The qualification of NetApp EF600 and BeeGFS file system for DGX SuperPOD is the latest addition to a complete set of AI solutions that have been developed by the companies.
“The NetApp and NVIDIA alliance has delivered industry-leading innovation for years, and this new qualification for NVIDIA DGX SuperPOD builds on that momentum,” said Phil Brotherton, Vice President of Solutions and Alliances at NetApp. “As performance and data demands are exploding, NVIDIA DGX SuperPOD, coupled with ONTAP AI platform and DGX Foundry AI service, ensures our customers get the best-in-class model training infrastructure, with the full support of AI industry leaders.”
“Organizations modernizing their business with AI and HPC need performance, flexibility and choice as they architect their infrastructure,” said Charlie Boyle, Vice President of DGX systems at NVIDIA. “Our collaboration with NetApp enables customers building their own AI Centers of Excellence to now choose NetApp storage for their NVIDIA DGX SuperPOD, as well as use the same leading platform available as hosted infrastructure through NVIDIA DGX Foundry.”
“We’re thrilled to be working with NetApp and NVIDIA to build an HPC/AI Center of Excellence with NVIDIA DGX systems so applied learning students can experience supercomputing and high-performance computing infrastructure,” said Tonya Witherspoon, Associate Vice President, Industry Engagement & Applied Learning at Wichita State University. “NetApp is a digital fabric anchor of the innovation campus, and we can’t wait to develop the next generation of talent in this exciting space.”
Broad Portfolio of AI Infrastructure Solutions
NetApp’s portfolio of NVIDIA-accelerated solutions includes ONTAP AI to eliminate guesswork for faster adoption by using a field-proven reference architecture as well as a preconfigured, integrated solution that is easy to procure and deploy in a turnkey manner.
Also included is NVIDIA DGX Foundry , which features NVIDIA Base Command software and NetApp Keystone Flex Subscription. This combination provides a world-class hosted infrastructure solution for businesses and their data scientists who need a premium AI development experience without the struggle of building it themselves.
With today’s announcement, organizations can also build their AI Centers of Excellence leveraging the power of DGX SuperPOD on premises in combination with NetApp storage.
NetApp, in collaboration with NVIDIA, also offers tailored solutions for a variety of industries, including financial services , medicine , manufacturing , retail , higher education and government, and has sponsored and facilitated ideation workshops for customers embarking on AI journeys to accelerate success while mitigating risk.
“The AI lifecycle focus has moved up the development stack and away from the infrastructure management, driving the need for converged solutions and services that make it easier for organizations to simplify their infrastructure investments for AI use cases deployments,” said Ritu Jyoti, Group Vice President, AI/Automation Research & Advisory at IDC. “DGX SuperPOD is the latest milestone in a prolific partnership between NetApp and NVIDIA to address this need, and NetApp is well positioned to help customers solve their data management challenges regardless of where it resides.”
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom